These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27039292)

  • 1. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
    J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment.
    Buglioni S; Vici P; Sergi D; Pizzuti L; Di Lauro L; Antoniani B; Sperati F; Terrenato I; Carosi M; Gamucci T; Vincenzoni C; Mariani L; Vizza E; Venuti A; Sanguineti G; Gadducci A; Barba M; Natoli C; Vitale I; Mottolese M; De Maria R; Maugeri-Saccà M
    Oncoimmunology; 2016 Jun; 5(6):e1160187. PubMed ID: 27471633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Shaaban AM; Humphries MP; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    J Cell Physiol; 2017 Aug; 232(8):2246-2252. PubMed ID: 27987320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
    Melucci E; Casini B; Ronchetti L; Pizzuti L; Sperati F; Pallocca M; De Nicola F; Goeman F; Gallo E; Amoreo CA; Sergi D; Terrenato I; Vici P; Di Lauro L; Diodoro MG; Pescarmona E; Barba M; Mazzotta M; Mottolese M; Fanciulli M; Ciliberto G; De Maria R; Buglioni S; Maugeri-Saccà M
    J Transl Med; 2018 Feb; 16(1):22. PubMed ID: 29402328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
    Ercolani C; Di Benedetto A; Terrenato I; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Buglioni S; Ramieri MT; Mentuccia L; Gamucci T; Perracchio L; Pescarmona E; Mottolese M; Barba M; Vici P; De Maria R; Maugeri-Saccà M
    Cancer Biol Ther; 2017 May; 18(5):339-346. PubMed ID: 28387539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
    Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
    J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
    Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
    J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
    Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
    Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
    Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
    Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
    Khanal P; Yeung B; Zhao Y; Yang X
    Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.
    Maugeri-Saccà M; Barba M; Pizzuti L; Vici P; Di Lauro L; Dattilo R; Vitale I; Bartucci M; Mottolese M; De Maria R
    Expert Rev Mol Med; 2015 Jul; 17():e14. PubMed ID: 26136233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
    Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
    Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.